First Tracks Biotherapeutics is trading at $36.23, up 5.24%, with no confirmed company-specific announcement or catalyst dated September 28, 2026.

  • A Guggenheim Buy rating was reported September 16; it is earlier context, not a confirmed explanation for the move.
  • Broader markets are lower: the S&P 500 is down 0.83%, Nasdaq 1.02%, and Dow 0.74%. The gain does not appear to track broad-market direction.
  • No volume or unusual-activity data was provided.